CryoPort, Inc. (NASDAQ:CYRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

CryoPort, Inc. (NASDAQ:CYRX) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $15.3125.

Several research analysts have recently commented on the company. Needham & Company LLC boosted their target price on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Guggenheim boosted their target price on CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings raised CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Wall Street Zen raised CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Finally, KeyCorp boosted their target price on CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th.

Insider Transactions at CryoPort

In other news, CFO Robert Stefanovich sold 38,700 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total value of $300,312.00. Following the transaction, the chief financial officer directly owned 255,701 shares of the company’s stock, valued at $1,984,239.76. The trade was a 13.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerrell Shelton sold 7,918 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the transaction, the chief executive officer directly owned 1,054,501 shares in the company, valued at $8,436,008. The trade was a 0.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 59,939 shares of company stock valued at $471,183 in the last three months. 10.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC lifted its holdings in CryoPort by 23.8% during the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after buying an additional 623,896 shares in the last quarter. Vanguard Group Inc. lifted its holdings in CryoPort by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock worth $27,094,000 after buying an additional 69,550 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in CryoPort by 0.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company’s stock worth $12,384,000 after buying an additional 8,280 shares in the last quarter. UBS Group AG lifted its holdings in CryoPort by 6.8% during the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock worth $13,650,000 after buying an additional 90,363 shares in the last quarter. Finally, Mak Capital One LLC lifted its holdings in CryoPort by 46.6% during the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock worth $11,513,000 after buying an additional 381,063 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

CryoPort Trading Down 2.8%

CYRX stock opened at $15.70 on Friday. CryoPort has a 1-year low of $6.16 and a 1-year high of $16.73. The firm has a market cap of $791.28 million, a P/E ratio of 11.63 and a beta of 1.90. The business’s 50 day moving average is $11.75 and its 200-day moving average is $10.11.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The company had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million. Sell-side analysts forecast that CryoPort will post -0.85 EPS for the current year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.